BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, January 14, 2025
See today's BioWorld
Home
» HemaQuest Expands Series B, Adds $13M for Sickle Cell Drug
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
HemaQuest Expands Series B, Adds $13M for Sickle Cell Drug
March 13, 2012
By
Marie Powers
No Comments
San Diego biotech HemaQuest Pharmaceuticals Inc. closed a $13 million extension of its Series B financing to fund a Phase IIb study of its lead candidate HQK-1001 in sickle cell disease.
BioWorld
